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Epilepsy is a chronic neurological disorder requiring long-term therapy using 
antiepileptic medications. Reports have incriminated long-term antiepileptic drugs 
use in deficiency of vitamin D and bone diseases in all age groups. We aimed 
to investigate the association between serum 25-hydroxyvitamin D levels and 
pediatric epilepsy in Indian patients.
Materials & Methods
We prospectively recruited 100 pediatric epilepsy patients, on monotherapy for 
minimum one-year duration, and 50 age and sex matched controls. This study was 
carried out at Yashoda Hospital, India  from 2011-2014. All cases and controls 
underwent tests for serum 25-hydroxyvitamin D, alkaline phosphatase, serum 
calcium and phosphorus levels.
Results
Patients with 25-hydroxyvitamin D deficiency were significantly higher among 
cases (45%) than controls (24%). Mean alkaline phosphatase was significantly 
higher in cases and mean serum calcium was significantly lower (8.3±1.5) in 
cases. Amongst antiepileptic drugs, carbamazepine and sodium valproate were 
significantly associated with 25-hydroxyvitamin D deficiency. Risk of vitamin D 
deficiency was highest with sodium valproate usage (odds:4.0;95%CI 1.4-11.6) 
followed by carbamazepine use (odds: 2.7; 95%CI 1.0-6.8). After adjustment 
using multiple logistic regression, antiepileptic drugs showed independent 
association with 25-hydroxyvitamin D deficiency (odds:2.2;95%CI 0.9-4.5). 
Conclusion
25-hydroxyvitamin D deficiency was significantly associated with use of 
carbamazepine and sodium valproate in pediatric epilepsy.
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Introduction 
Epilepsy is a common neurological disorder that affects all age groups. Globally, 
around 50 million people are affected with epilepsy, which corresponds to 0.5% of 
the global burden of all diseases, in developing countries (1). In India, more than 10 
million people suffer with seizures and prevalence of epilepsy is one percent in our 
population (2). The frequency rates for children vary from 2.0 to 22.2 per 1000 (3) 
and nearly 50% of all epileptics suffer from their childhood (4). 
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other systemic diseases or with neurological deficits and 
controlswith any history of illness or taking vitamin D 
supplements were excluded in the study.
Standardized questions were adapted from behavioral 
risk factors questionnaire by the Centers for Disease 
Control and Prevention (CDC) (9). Patients’ data 
were collected through face-to-face interviews from 
patients’ parents among cases and control subjects by 
a senior epileptologist. Patient medical history, type 
of AEDs, physical and neurological examination was 
done by a senior neurologist. All cases and controls 
underwent estimation of serum alkaline phosphatase, 
serum calcium and serum phosphorus. 
Assessment of 25-hydroxyvitamin D
For measurement of 25-hydroxyvitamin D, 5 ml 
blood was collected from both cases and controls. We 
used chemiluminescent microparticle immunoassay 
(CMIA) with automated instruments for assessment of 
25-hydroxyvitamin D. We considered serum levels of 
25 hydroxyvitamin D < 20 ng/mL as deficiency and 
>20.1 ng/mL as sufficient (7). 
Statistical analysis
Statistical analysis was applied by SPSS ver. 15.0 
(Chicago, IL, USA) software. Mean and standard 
deviation (SD) were estimated for various variables. 
Categorical variables were expressed as proportions 
and chi-square test was used to study the association 
in proportions. The student ‘t’ test was used to test the 
differences in continuous variables. We performed 
multiple logistic regression analysis before and 
after adjustment for various AEDs (Carbamazepine, 
clobazam, clonazepam, lamotrigine, phenobarbital, 
sodium valproate, topiramate). All tests were two 
sided and P value <0.05 was considered statistically 
significant.
Results 
We noted boys constituted 60% in both cases and controls. 
Mean age was 14 yrs in cases and 14.5 yrs in controls 
with age range of 8-18 yrs. We found significantly 
higher prevalence of deficiency of 25-hydroxyvitamin 
D, (P<0.0001) mean alkaline phosphatase (P<0.0001) 
and serum calcium (P=0.01) in cases compared to 
Epilepsy patients require longtime antiepileptic drugs 
(AEDs). Long-term usage of AEDs is associated with 
abnormal bone mineral metabolism, osteoporosis and 
an increased risk of fracture (5). The main mechanism 
seems to be centered on vitamin D deficiency caused by 
AEDs in epilepsy patients (6). 
The structure of vitamin D is a 9,10 -seco steroid and two 
types are dominantly present in humans (vitaminD3and 
vitamin D2). In circulation, vitamin D exists as serum 
25-hydroxyvitamin D and this serves as a marker of 
vitamin D levels in the body. Vitamin D plays a vital 
role in maintaining a balance between phosphorus 
and calcium levels as well as metabolism. Vitamin D 
deficiency can cause reduced bone mineralization and 
bone fractures (7). 
The aim of the present study was to investigate the 
circulating blood levels of serum 25-hydroxyvitamin D 
in pediatric epilepsy patients who were on AEDs. Very 
limited data is available from the Indian Subcontinent.
Material and Methods
We selected 100 consecutive pediatric epilepsy cases, 
with age below 18 yr and 50 age and sex matched 
controls. This study was carried out at Department 
of Neurology, Yashoda Hospital, Hyderabad, India 
from January 2011 to December 2014. This study was 
approved by Institutional Ethics Committee. Informed 
consent was taken from the subjects.
Definition of cases and controls 
Epilepsy is a disease of the brain, which results in 
predisposition to have epileptic seizures. Epilepsy is 
diagnosed when there is occurrence of at least two 
unprovoked seizures, occurring at least 24 hours apart 
(8). Controls were recruited from healthy subjects 
(children of staff or volunteers) from same hospital. 
Inclusion and exclusion criteria of case controls
Patients who gave history of two attacks of seizures 
at least 24 hours apart in their life and were on 
monotherapy with antiepileptic drugs for minimum one 
year were included. Healthy controls without any history 
of seizures, rickets or other bone related disorders were 
included in the study. Patients who were on two or more 
AEDs, taking vitamin D supplements, suffering from 
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Discussion 
In our study, 25-hydroxyvitamin D (≤20 ng/mL) 
deficiency was significantly higher among epileptics 
(44%) compared to control subjects (20%), which 
is a constant finding noted by similar studies (6, 10, 
11). Twenty five percent of children with epilepsy 
had deficiency of 25-hydroxyvitamin D (10). Serum 
25-hydroxyvitamin D deficiency was 75% of children 
with epilepsy (12). 
We also found significantly lower mean calcium levels 
in epileptic patients compared to controls (P= 0.01), 
our observation was advocated by others (12-14). 
The mechanism underlying low levels of calcium in 
epileptics may be multifactorial. AEDs are associated 
with alterations in bone metabolism and phosphate 
concentration and thus a change in calcium homeostasis 
in the body (15). However, some studies have found no 
significant association of calcium levels with epilepsy 
(16-18). 
We noted mean alkaline phosphatase levels were 
significantly higher in epileptic patients compared to 
controls (P<0.0001) similar to other studies (4, 15, 16). 
Elevated alkaline phosphatase levels are associated with 
liver or bone disease. In the present study, high alkaline 
controls (Table 1). 
Mean serum alkaline phosphatase (P=0.001), serum 
calcium (P=0.0006) and mean duration of taking 
AEDs (P<0.0001) were significantly higher among 
25-hydroxyvitamin D deficient cases compared to cases 
with normal 25-hydroxyvitamin D levels (Table 2).
Regarding AEDs, the percentage taking carbamazepine 
was 27(27%), clobazam 6(6%), clonazepam 7(7%), 
lamotrigine 6(%), phenobarbital 24(24%), sodium 
valproate 21(21%) and topiramate 9(9%). Significantly 
higher prevalence of 25-hydroxyvitamin D deficiency 
was noted with carbamazepine (P=0.04) and sodium 
valproate (P=0.01) usage (Figure 1). 
On odds ratio analysis, we established independent 
association of 25-hydroxyvitamin D deficiency with 
AEDs use. Carbamazepine (odds:2.7;95%CI:1.0-6.8) 
and sodium valproate (odds:4.0;95%CI:1.4-11.6) 
were associated more in comparison to phenobarbital 
(odds:2.0; 95%CI:0.8-5.1), and and topiramate 
(odds:0.5;95%CI:0.1-2.4) use (Table 3). 
After adjustment with multiple logistic regression 
analysis, antiepileptic drugs use was independently 
associated with deficiency of 25-hydroxyvitamin D in 
pediatric epilepsy patients (Table 4).








Male child 60(60%) 30(60%) 0.8
Female child 40(40%) 20(40%) 0.8
Mean age (years) 14±2.2 14.5±2.5 0.8
Age range (years) 8-18 8-18
Range of 25-hydroxyvitamin D value 9-25 15-30
25-hydroxyvitamin D deficiency 45(45%) 12(24%) =0.004
Mean 25-hydroxyvitamin D deficiency 18.3±6.2 27.7±3.9 <0.0001
Mean alkaline Phosphatase 564.3±157.3 386±294.7 <0.0001
Mean serum calcium 8.3±1.5 8.9±1.2 =0.01
Mean serum phosphorus 2.8±0.1 2.7±0.9 0.2
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Apart from its action on vitamin D, AEDs also have 
had an independent association with both increased 
parathormone levels and increased bone turnover (22).
In this study, most commonly used antiepileptic drug 
was carbamazepine in 27%, phenobarbital in 24%, 
sodium valproate in 21%, topiramate in 9%, clonazepam 
7%, clobazam 6% and lamotrigine in 6% of patients. 
Our study established that 25-hydroxyvitamin 
D deficiency was significantly associated with 
carbamazepine (37.7%) and sodium valproate (31.1%) 
usage; similar studies have advocated our findings (4, 
6, 23, 24). Misra et al. found 25-hydroxyvitamin D 
deficiency in 21.7% of patients on carbamazepine (4). 
A higher prevalence of 25-hydroxyvitamin deficiency 
(50%) with carbamazepine usage was noted (25). 
Verrotti et al. established an independent association 
between 25-hydroxyvitamin D deficiency and AEDs 
usage (26). However, some studies did not find any 
significant association of carbamazepine and sodium 
valproate usage with deficiency of 25-hydroxyvitamin 
D (27).
The present study showed no significant association 
between 25-hydroxyvitamin D deficiency with long-
term administration of phenobarbital and topiramate. 
However, some studies have found deficiency of 
25-hydroxyvitamin D with phenobarbital and topiramate 
(28, 29).
phosphatase levels are indicative of high bone turnover 
rather than liver disease as other hepatic parameters are 
normal. 
The present study established that mean 
25-hydroxyvitamin D levels was significantly lower 
in cases (18.3±6.2) compared to controls (27.7±3.9)
(P<0.0001). In similar a study, the mean level of 
25-hydroxyvitamin D was lower among cases (28.79 
± 33.85) in contrast to controls (mean 47.62 ± 46.16) 
(19). However, some studies have found no relationship 
between deficiency of 25-hydroxyvitamin D and 
epilepsy (15, 16, 20).
We noted that among epileptics, elevated alkaline 
phosphatase and low serum calcium were significantly 
associated with deficiency of 25-hydroxyvitamin D 
(P=0.0001), accounted by others (12-14, 21).
Thus in our study the main pathogenetic mechanism 
seems to be based on reduced active levels of vitamin 
D, possibly caused by induction of hepatic cytochrome 
P450 enzymes by AEDs, leading to its conversion 
to inactive metabolites in the liver microsomes. 
Hypocalcemia can be due to decreased absorption from 
the gut secondary to the state of hypovitaminosis D. This 
may then trigger an increase in circulating parathyroid 
hormone. The secondary hyperparathyroidism then 
leads to an increased bone turnover leading to increased 
serum alkaline phosphatase levels (21).
Association of 25-Hydroxyvitamin D Deficiency in Pediatric Epilepstic Patients
Table 2. Comparison between 25-Hydroxyvitamin D Deficient and Normal 25-Hydroxyvitamin D levels in Cases







Male 32(58.1%) 27(60%) 0.9
Female 23(41.8%) 18(40%) 0.9
Mean age (years) 13.7±2.4 14.1±1.9 0.3
Age range (years) 8-18 9-18
Mean Elevated alkaline Phosphatase 523.9±139.8 619.7±159.8 =0.001
Mean serum calcium 8.7±1.4 7.7±1.4 =0.0006
Mean serum phosphorus 2.9±0.5 2.8±0.6 0.3 
Mean length of taking AEDs in months 25.2±10.5 40.4±12.8. <0.0001
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other mechanism postulated include reduced intestinal 
calcium absorption (phenytoin) (34), impaired response 
to parathyroid hormone (phenobarbitone and phenytoin), 
(35) hypovitaminosis K (phenytoin) (36), and calcitonin 
deficiency (37). The exact mechanism by which sodium 
valproate causes similar bone mineral metabolism 
abnormalities is not clear but it may be mediated by a 
different hepatic enzyme inhibition (38). Multi-drug 
therapy is associated with high risk of bone mineral 
metabolism abnormalities than monotherapy (24). 
There has been a lot of debate on whether the enzyme 
inducing properties of AEDs are to blame. Initial studies 
reported an association of reduced bone mineral density 
and increased fracture risk with mainly enzyme inducing 
AEDs (EIAEDs) (39, 40). However, recent studies have 
found no difference between EIAEDs and Non-EIAEDs 
in their action on 25-hydroxyvitamin D status (41). There 
was a similar risk of developing vitamin D deficiency 
with both EIAEDs and Non-EIAEDs (42). In our study 
too, both EIAEDs (carbamazepine (odds 2.7;95%CI:1-
0-6.8)) and Non- EIAEDs (sodium valproate (odds 
Vitamin D inactivation by AEDs occurs mainly by 
induction of hepatic enzymes and by their activation of 
pregnane X receptor (PXR) and steroid and xenobiotic 
receptors (SXR) (22, 30). Activation of vitamin D (D2 
and D3) occurs initially in the liver where they are 
hydroxylated to 25(OH) D by vitamin D hydroxylase 
CYP27A. The antiepileptic drug binds and activates 
SXR. This complex binds to RXR, which then activates 
the 24-hydroxylase enzyme by interacting with its 
vitamin D responsive element (31, 32). This enzyme 
mediates the removal of 25-hydroxyl group from both 
25-hydroxyvitamin D and 1,25 dihydroxy vitamin D. 
This accelerated inactivation of vitamin D causes a 
cascade of events to adapt to the progressive insufficiency 
leading to secondary hyperparathyroidism. Further 
hypovitaminosis D results in decreased absorption of 
calcium from the gut. It has a detrimental effect on bone 
mineralization and metabolism. 
The above mechanism have been attributed to AEDs 
which are inducers of cytochrome P450 enzyme system 
(phenobarbitol, phenytoin and carbamazepine) (33).The 
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Table3. Odds Ratio with Antiepileptic Medication
Antiepileptic drugs Odds ratio 95% CI 
Carbamazepine 2.7 1.0-6.8
Phenobarbital 2.0 0.8-5.1
Sodium valproate 4.0 1.4-11.6
Topiramate 0.5 0.1-2.4
Table 4. Predictors of Deficiency of 25-Hydroxyvitamin D in Pediatric Epilepsy
Before adjustment After adjustment 
Antiepileptic drugs Odds ratio 95% CI Odds ratio 95% CI 
Any medication 2.5 1.1-5.5 2.2 1.0-4.5
Individual medication
Carbamazepine 2.7 1.0-6.8 * *
Phenobarbital 2.0 0.8-5.1 * *
Sodium valproate 4.0 1.4-11.6 * *
Topiramate 0.5 0.1-2.4 * *
* Number of patients insufficient for statistical analysis
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4.0;95%CI:1-4-11.6)) were significantly associated with 
deficiency of 25-hydroxyvitamin D.
The duration of treatment especially long term 
usage of AEDs was significantly associated with 
25-hydroxyvitamin D deficiency (43-46). We found that 
epileptics with deficiency of 25-hydroxyvitamin D had 
significantly longer duration of treatment (mean during 
of treatment 40.4±12.8 in months) compared to those 
with normal 25-hydroxyvitamin D (25.2±10.5 months). 
However, some studies have found no correlation 
between 25-hydroxyvitamin D deficiency and duration 
of treatment with AEDs (15, 20). The exact duration of 
AEDs, which leads to vitamin D deficiency, is not clear. 
In a study by Cansu et al, vitamin D levels significantly 
decreased after 18 months of taking AEDs (43). In 
another study, 49% acquired vitamin D3 insufficiency 
within 3 months of AEDs (45). Farhat et al, noted that 
exposure to AEDs for more than six month leads to 
vitamin D deficiency in 35% (46). In our study the cohort 
of epileptics with normal vitamin D had a mean exposure 
time of 25.2 months which was considerably longer than 
the previous data, this may be because Indians have 
more exposure to sunlight. India is a tropical country and 
the study was conducted in South India in a city with the 
temperature during the day of 20-30 oC with only a 10 oC 
variation between winter and summer. 
This study reemphasizes the negative action of AEDs on 
bone mineral metabolism and is consistent with current 
worldwide literature (24). Vitamin D supplementation 
may help in preventing these complications. Several 
randomized controlled studies have shown a beneficial 
effect of vitamin D therapy with AEDs in children; 
however, the information regarding duration of therapy, 
role of diet/exercise and the role of monitoring to 
vitamin D levels are still lacking (47). They are currently 
no accepted guidelines for preventing and treating 
diseases of bone metabolism and vitamin D deficiency 
in epilepsy. Some authors suggest that doses as high 
Association of 25-Hydroxyvitamin D Deficiency in Pediatric Epileptic Patients
Fig 1. Different between normal and deficiency of 25-hydroxyvitmain 
D with various antiepileptic drugs 
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as 50,000 IU of vitamin D monthly would be needed 
to normalize vitamin D levels for patients with epilepsy 
(48). Others have recommended a supplementation 
dose of 400-4000 IU/day of 25-hydroxyvitamin D for 
treating these changes. For prophylaxis, two studies 
have recommended 600- 2000IU/ day of vitamin D for 
all epileptics as soon as they are started on AEDs and for 
treating osteomalacia they have recommended a dosage 
of 5000-15000IU/day of vitamin D (49, 50).
Most practicing neurologists do not consider this aspect 
while treating their epileptic patients. Prophylactic 
calcium or vitamin D supplementation is prescribed 
by only 9% of pediatric neurologists and 37% of 
neurologists, along with AEDs in epileptic patients (51). 
Our study had some limitations, the main inadequacy 
was that 25-hydroxyvitamin D levels were not 
measured before starting AEDs and hence we cannot 
categorically attribute the levels to AEDs use. Second 
drawback was that we did not assess bone density in 
both cases and controls due to both financial reasons 
and lack of standardized reference range for Indian 
children. Third, as our sample size was small, we were 
unable to perform multiple logistic regression analysis 
to study the association between individual AEDs and 
25-hydroxyvitamin D levels. Strengths of our study 
were that we recruited cases and controls from the same 
hospital thus reducing difference based on ethnicity, 
social customs and socioeconomic status. 
In conclusion, this study is further reemphasis the need 
to create more bone health awareness among epileptic 
patients and health care providers. We believe that 
all epileptic patients should be counselled regarding 
calcium and vitamin D intake, exposure to sunlight and 
physical activity, especially before initiation of AEDs. 
There should be precautionary assessment especially 
when starting on AEDs like carbamazepine and sodium 
valproate, which have an increased risk of impairing 
bone mineral metabolism. Further multicentric 
prospective studies are required to evaluate the role 
and formulate clear guidelines on prophylactic vitamin 
D supplementation and other measured needed for 
prevention and treatment of impaired bone metabolism 
in epilepsy. 
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